Xenon posts Phase 2 results for XEN1101 in major depressive disorder trial X-NOVASep 21Trial updateazetukalnerXenon Pharmaceuticals Inc.
Xenon reports Q2 2026 results, confirms azetukalner NDA submission on track for Q3Aug 6Clinical readoutazetukalnerXenon Pharmaceuticals Inc.
Sign inSign in